Mecamylamine for Autonomic Dysreflexia Prophylaxis

Spinal Cord Injuries Clinical Trial

Official title:

Pilot Study of Mecamylamine for Autonomic Dysreflexia Prophylaxis

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03914677
• Other study ID #: 080518MP2F
• Status: Recruiting
• Phase: Phase 4
• Start date: June 13, 2019
• Est. completion date: December 31, 2020

Study information

• Verified date: October 2019
• Source: Wayne State University
• Contact: Daniela Ristova-Trendov, MD
• Phone: 313/745-0590
• Email: dristova[@]med.wayne.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a preliminary study of the antihypertensive drug mecamylamine, used in the specific circumstance of hypertension caused by autonomic dysreflexia (AD), a condition that affects people with spinal cord injury (SCI). Initially, mild sensory stimulation of subjects' legs is used to intentionally provoke AD, as reflected by blood pressure elevation during such stimulation. In subsequent testing sessions, mecamylamine is given prior to sensory stimulation, to show the effect of the drug on preventing these AD-related blood pressure elevations.

Description:

In this one year pilot study we will enroll 3-5 people with SCI, and aim to develop a simple, convenient BP cuff method to elicit AD (i.e., using a BP cuff applied to the leg as a mild noxious stimulus), and then use that method to preliminarily evaluate the effects of the antihypertensive drug mecamylamine on AD. Study participants will complete up to 5 research visits, will undergo AD provocation using the leg cuff protocol, and will receive escalating doses of mecamylamine, as needed and tolerated, in order to prevent AD:

After signing the informed consent form, at visit 1, subjects will complete an interview to evaluate past medical history, an autonomic dysfunction questionnaire, a physical examination (including an autonomic assessment and specialty SCI exam), vital signs measurement, and baseline testing of the electrical activity of the heart (electrocardiography or ECG testing).

At visit 2, subjects will complete a preparation procedure including: baseline vital signs measurement, an interview to document all medications and/or supplements taken in the prior 24 hours, confirmation of completed bladder/bowel evacuation before the visit, confirmation of no significant illness/injury since last visit, and documentation of any meals before the visit. Next, the subject will be connected to an ECG monitor and a (second) BP cuff will be applied to the arm (for measuring BP response to the leg cuff procedure). With the ECG and arm cuff in place, s/he will undergo the AD provocation procedure: The BP cuff placed around the leg just below the knee will be inflated for up to 10 minutes, as a means of providing sensory stimulation to elicit AD. BP will be measured using the arm cuff every 2 minutes during the leg cuff inflation, and periodically after the leg cuff is deflated, until BP and heart rate are back to baseline values. Physical manifestations and symptoms of AD will be recorded during the period of leg cuff inflation and thereafter, throughout recovery. This BP cuff protocol will be repeated twice during the same visit, with trials separated by a 30-minute recovery period. The leg cuff will be deflated immediately if the blood pressure-measuring cuff shows that systolic BP exceeds 180 mmHg, diastolic BP exceeds 100 mmHg, heart rate is less than 40 or greater than 100 beats per minute, adverse ECG changes are evident, or symptoms are unacceptable to the subject. An established safety plan will be followed in the event of a significant adverse reaction to the leg compression or study drug. If the leg cuff inflation fails to elicit AD, then the subject will be dropped from the study.

At visit 3, a similar visit preparation procedure will be completed as in visit 2. Three hours prior to AD provocation testing with the leg cuff, subjects will receive 2.5 mg of mecamylamine in tablet form, to try to prevent AD. Physical manifestations and symptoms of AD will be recorded during the period of cuff inflation and thereafter, throughout recovery. The leg cuff will be deflated after 10 minutes, or immediately as appropriate according to the same criteria as listed for visit 2. After a 30-minute recovery, the leg cuff inflation will be repeated once during the same session, to confirm whether or not 2.5 mg of mecamylamine eliminates AD, or at least reduces the associated BP elevation, as well as the other manifestations and symptoms. If the dose of 2.5 mg mecamylamine is effective, the subject will not be asked to return for testing with a higher dose and study participation will end with visit 3. If either trial of leg cuff inflation still elicits AD despite premedication with 2.5 mg mecamylamine, then s/he will be scheduled to come back for visit 4.

At visit 4, the visit preparation will be completed as in visits 2 and 3. Three hours prior to testing with the AD provocation procedure, 5 mg of mecamylamine will be given to the participant to try to prevent AD, since the lower dose failed to do so. The same procedures described above for visit 3 will be followed; subjects will again undergo 2 trials of AD provocation with the leg squeezing procedure. If both are successful (i.e., no AD is observed), the subject's participation in the study will end. If, despite premedication with mecamylamine 5 mg, the subject still experiences AD, then s/he will be asked to return for visit 5.

At visit 5, all the procedures as in visit 4 will be repeated, except that subjects will receive 7.5 mg of mecamylamine. Regardless if the medication does not prevent AD, subjects will not be scheduled to come for a follow up, as no further dose escalation will be attempted.

If at visit 3, 4, or 5 a subject experiences symptomatic low blood pressure after taking mecamylamine (manifest as dizziness, lightheadedness, or change in vision; this is considered unlikely based on the published literature), s/he will be asked to drink several glasses of cold water, and possibly to lay down for up to 30 minutes to try to alleviate those symptoms. In the event symptomatic low blood pressure persists, the subject will be given 10 mg of midodrine, a medication to elevate blood pressure. Midodrine would be expected to promptly (in less than an hour) elevate blood pressure and alleviate those symptoms. Upon adequate elevation of blood pressure to cause resolution of the symptoms, the subject will be discharged from the study, because of the adverse effect of mecamylamine. If the midodrine 10 mg fails to resolve symptomatic low blood pressure, then further evaluation and treatment will be provided as appropriate (e.g., intravenous fluids). The latter scenario is considered to be extremely unlikely.

note - visits will be separated by no more than one month

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 5
• Est. completion date: December 31, 2020
• Est. primary completion date: March 17, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• chronic (>1 year) SCI at T6 or above, American Spinal Injury Association grade A, B, or C

• negative serum pregnancy test for females

Exclusion Criteria:

• history of arrhythmia, cardiovascular disease, cerebral aneurysm

• contraindications to use of mecamylamine or midodrine (pregnancy, nursing, glaucoma, kidney disease, pyloric stenosis, arteriosclerosis, or concurrent use of a sulfonamide antibiotic)

• dependence on reflex voiding for bladder management (mecamylamine may cause urinary retention)

Related Conditions & MeSH terms

• Autonomic Dysreflexia
• Spinal Cord Injuries

Intervention

Drug:
• Mecamylamine Oral Tablet
nicotinic antagonist (ganglionic blocker)

Locations

Country	Name	City	State
United States	Wayne State University	Detroit	Michigan

Sponsors (1)

Lead Sponsor	Collaborator
Wayne State University

Country where clinical trial is conducted

United States, 

References & Publications (4)

Braddom RL, Johnson EW. Mecamylamine in control of hyperreflexia. Arch Phys Med Rehabil. 1969 Aug;50(8):448-53 passim. — View Citation

Braddom RL, Rocco JF. Autonomic dysreflexia. A survey of current treatment. Am J Phys Med Rehabil. 1991 Oct;70(5):234-41. — View Citation

Eldahan KC, Rabchevsky AG. Autonomic dysreflexia after spinal cord injury: Systemic pathophysiology and methods of management. Auton Neurosci. 2018 Jan;209:59-70. doi: 10.1016/j.autneu.2017.05.002. Epub 2017 May 8. Review. — View Citation

Groothuis JT, Rongen GA, Deinum J, Pickkers P, Danser AH, Geurts AC, Smits P, Hopman MT. Sympathetic nonadrenergic transmission contributes to autonomic dysreflexia in spinal cord-injured individuals. Hypertension. 2010 Mar;55(3):636-43. doi: 10.1161/HYPERTENSIONAHA.109.147330. Epub 2010 Jan 25. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	change in systolic blood pressure	difference in systolic blood pressure during leg cuff inflation vs during unstimulated baseline	10 minutes (following initiation of sensory stimulation)
Primary	change in heart rate	difference in heart rate during leg cuff inflation vs during unstimulated baseline	10 minutes (following initiation of sensory stimulation)
Secondary	signs and symptoms of autonomic dysreflexia	piloerection, diaphoresis, headache	10 minutes (following initiation of sensory stimulation)